A procedure known as the "lunchtime boob job" will no longer be available in the United Kingdom.

According to BBC News, the Medicines and Healthcare products Regulatory Agency (MHRA) decided to ban the cosmetic procedure because of worries that the injectable used, Macrolane, could affect mammogram readings and make diagnosis more difficult.

The company that manufactures the substance has agreed to the ban as well.

"Q-Med has decided to stop promoting the use of Macrolane in breast enhancement until consensus has been reached regarding best practices in breast radiology examination following Macrolane treatment," according to a statement on the company's website.

The British Association of Aesthetic Plastic Surgeons (BAAPS) supported the decision, after a survey revealed that as many as 25 percent of its members have noticed patient complications from the filler.

"Any treatment can only be considered safe once it is known what long-term effect it has on cancer screening," BAAPS president Fazel Fatah told the news provider.

Unlike traditional breast augmentation surgery, the so-called lunchtime boob job is a non-invasive procedure in which Macrolane is injected into the breasts. The substance, which is not used in the US, is still approved for use in the UK for body contouring and correcting soft tissue defects. However, like other injectables, it is only a temporary solution and needs to be repeated every nine to 12 months in order to maintain results.

Similar “lunchtime” procedures are advertised in the US from breast augmentations to facelifts. These quick-fix procedures usually boast a radically reduced recovery time and more economical pricing, but often do not tell the whole story. The American Society for Aesthetic Plastic Surgery recommends exercising caution when dealing with discounted, quick-fix plastic surgery centers. Patients should make sure their doctors are board-certified in plastic surgery and performing surgery in an accredited facility.